Q2 2026 saw strong revenue growth, driven by proprietary products and the successful integration of LUMRYZ. The orexin pipeline advanced with positive clinical data, while commercial execution and expanded access for key brands support long-term growth.Based on Alkermes plc [ALKS] Q2 2026 Audio Tra…
Alkermes plc. reported second-quarter 2026 results with revenue of $496M, up 26.9% year over year, while net income fell to $0.5M and diluted EPS was $0 for the quarter.Financial HighlightsBusiness HighlightsOriginal SEC Filing: Alkermes plc. [ ALKS ] - 10-Q - Jul. 28, 2026This is an AI-powered sum…
Q2 2026 saw revenues rise to $496M, driven by the addition of LUMRYZ and strong LYBALVI sales, but net income dropped sharply due to higher expenses and interest from the Avadel Acquisition. The company completed a $2.3B acquisition, issued $1.5B in new debt, and faces ongoing litigation and contin…
Alkermes terminated its Authorized Generic Product Supply Agreement with Amneal on Jul 06, 2026. The deal, originally signed on Sep 09, 2025, covered U.S. distribution of an authorized generic of Vivitrol with supply pricing and profit-sharing terms. The termination was effectively mutual, carried…
